Nutriventia has launched sustained-release Prolanza ashwagandha, following the completion of a study on its pharmacokinetics. The product will officially be debuted at SupplySide West in Las Vegas, NV at booth 3827.
 
In the recent study, researchers investigated the pharmacokinetics, safety, and tolerability of 600 mg of Prolanza sustained-release capsules compared to 600 mg of a well-known ashwagandha extract.
 
Fourteen participants were randomized to receive either the test or the reference product as a single dose of two capsules in sequence under fasting conditions. Plasma concentrations of total withanolides, withanolides A, and 12-deoxywithastramonolide were measured using liquid chromatography-mass spectroscopy.
 
Prolanza exhibited a higher relative absorption, better bioavailability, and a longer elimination half-life than the control ingredient, indicating a sustained-release profile, the researchers concluded. “The relative bioavailability of the test formulation was 12, 44, and 11 times higher for total withanolides, withanolide A, and 12-deoxywithastramonolide, respectively,” they wrote.
 
The pharmacokinetic study also reports for first time, the successful plasma estimation of withanolide A and 12-deoxywithastraamonolide, the major phytoactives of ashwagandha.
 
“As ashwagandha is primarily consumed for its adaptogenic and stress response-reduction properties, the longer duration of Prolanza’s therapeutic effects will provide a stronger cumulative health value,” said Anand Godbole, Nutriventia vice president of marketing. “Consumers are looking for efficient products that will make their lives even a little easier. Prolanza provides that, plus convenience for our customers. Now with our clinical study showing adaptogenic support for a prolonged period, it makes Prolanza an ideal ingredient to help manage the grind of daily stress more efficiently. Consumers will be able to enjoy a higher sense of well-being and good health sooner with Prolanza sustained-release ashwagandha.”
 
The release pattern of Prolanza enables it to exert benefits for a prolonged duration with a single daily dose, according to the study, and is standardized to a broad spectrum of 20 withanolides, including 10 withanolides which have a USP monograph.